MX2022010939A - Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao). - Google Patents

Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao).

Info

Publication number
MX2022010939A
MX2022010939A MX2022010939A MX2022010939A MX2022010939A MX 2022010939 A MX2022010939 A MX 2022010939A MX 2022010939 A MX2022010939 A MX 2022010939A MX 2022010939 A MX2022010939 A MX 2022010939A MX 2022010939 A MX2022010939 A MX 2022010939A
Authority
MX
Mexico
Prior art keywords
daao
inhibitors
novel substituted
substituted derivatives
aminoacid oxidase
Prior art date
Application number
MX2022010939A
Other languages
English (en)
Inventor
Yufeng Jane Tseng
yu-li Liu
Chung-Ming Sun
Wen-Sung Lai
Chih-Min Liu
Hai-Gwo Hwu
Original Assignee
Yufeng Jane Tseng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yufeng Jane Tseng filed Critical Yufeng Jane Tseng
Publication of MX2022010939A publication Critical patent/MX2022010939A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona novedosos derivados sustituidos de benzimidazol utilizados como inhibidores de DAAO y para el tratamiento y/o prevención de trastornos neurológicos.
MX2022010939A 2016-09-14 2019-03-07 Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao). MX2022010939A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662394479P 2016-09-14 2016-09-14

Publications (1)

Publication Number Publication Date
MX2022010939A true MX2022010939A (es) 2022-10-07

Family

ID=61619704

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002726A MX2019002726A (es) 2016-09-14 2017-09-14 Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao).
MX2022010939A MX2022010939A (es) 2016-09-14 2019-03-07 Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019002726A MX2019002726A (es) 2016-09-14 2017-09-14 Novedosos derivados sustituidos como inhibidores de la d-aminoacido oxidasa (daao).

Country Status (12)

Country Link
US (4) US11370775B2 (es)
EP (2) EP3512840B1 (es)
JP (2) JP7029129B2 (es)
KR (3) KR20240042153A (es)
CN (2) CN116675674A (es)
AU (3) AU2017326359B2 (es)
CA (2) CA3207747A1 (es)
ES (1) ES2974883T3 (es)
IL (2) IL265108B2 (es)
MX (2) MX2019002726A (es)
TW (1) TWI659022B (es)
WO (1) WO2018053161A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11370775B2 (en) * 2016-09-14 2022-06-28 Yufeng Jane Tseng Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors
MX2022007854A (es) * 2021-06-23 2022-12-26 Yoda Pharmaceuticals Inc Derivados del benzimidazol para el tratamiento y/o la prevención de enfermedades y trastornos mediados por el nlrp3.

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434267B (sv) * 1974-02-18 1984-07-16 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
ZA825106B (en) * 1981-08-13 1983-04-27 Haessle Ab Novel pharmaceutical compositions
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
JPS6150979A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DE3509333A1 (de) * 1985-03-15 1986-09-18 Hoechst Ag, 6230 Frankfurt Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
JPS62201884A (ja) * 1986-02-28 1987-09-05 Tokyo Tanabe Co Ltd ベンズイミダゾール誘導体及びその製造法
US4745667A (en) 1987-07-20 1988-05-24 Victoria Creations, Inc. Closure device and buckle
ZA889194B (en) 1987-12-11 1989-08-30 Byk Gulden Lomberg Chemisch Fa Novel benzimidazole derivatives
JPH0347123A (ja) 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
SE9002206D0 (sv) * 1990-06-20 1990-06-20 Haessle Ab New compounds
CA2053527C (en) * 1990-10-17 2002-03-12 Takashi Sohda Pyridine derivatives, their production and use
GB9208492D0 (en) 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
GB9304500D0 (en) 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
DK72693D0 (da) * 1993-06-18 1993-06-18 Lundbeck & Co As H Compounds
GB9321221D0 (en) 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
EP1085846A2 (en) * 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2003039540A2 (en) 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
US20070197610A1 (en) 2004-03-16 2007-08-23 Janssen Pharmaceutica N.V. Benzisoxazoles
RU2410382C2 (ru) * 2005-03-17 2011-01-27 Тиботек Фармасьютикалз Лтд 1, 3-дигидробензимидазол-2-илиденовые амины в качестве ингибиторов репликации респираторного синцитиального вируса
WO2007133983A2 (en) * 2006-05-08 2007-11-22 Pharmacopeia, Inc. 2-aminobenzimidazoles for treating neurodegenerative diseases
CN101450939B (zh) * 2007-12-05 2013-06-19 沈阳药科大学 新型苯并咪唑类化合物
CA2740095A1 (en) * 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
CZ302612B6 (cs) 2010-11-01 2011-08-03 Zentiva, K.S. Kmen mikroorganismu Bacillus sp. B71 CCM 7718
GB201111705D0 (en) * 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
US20130231372A1 (en) * 2012-03-01 2013-09-05 Mary Matsui Small Molecule Inhibitors Of P-type ATPases
KR101435496B1 (ko) * 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
JP6322644B2 (ja) * 2012-11-26 2018-05-09 エムキュア ファーマシューティカルズ リミテッド 酸分泌阻害薬としてのピリドン誘導体およびその製造方法
JP6346904B2 (ja) * 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
SG11201504704TA (en) * 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
KR20160147868A (ko) * 2014-04-30 2016-12-23 위펑 제인 쳉 D-아미노산 옥시다제 억제제로서 공지된 화합물의 용도
EP3050565A1 (en) 2015-01-27 2016-08-03 Ecole Polytechnique Fédérale de Lausanne (EPFL) Benzimidazole sulfide derivatives for the treatment or prevention of tuberculosis
US11370775B2 (en) * 2016-09-14 2022-06-28 Yufeng Jane Tseng Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors
JP7132291B2 (ja) * 2020-08-31 2022-09-06 キオクシア株式会社 メモリシステムおよび制御方法

Also Published As

Publication number Publication date
IL307576B1 (en) 2025-02-01
CN116675674A (zh) 2023-09-01
EP3512840C0 (en) 2024-03-06
ES2974883T3 (es) 2024-07-02
JP7029129B2 (ja) 2022-03-03
CN110234635B (zh) 2023-03-10
US12129242B2 (en) 2024-10-29
KR20190049815A (ko) 2019-05-09
US20250250249A1 (en) 2025-08-07
AU2017326359A1 (en) 2019-03-21
EP3512840A4 (en) 2020-09-16
KR102409502B1 (ko) 2022-06-16
TW201811754A (zh) 2018-04-01
IL265108B1 (en) 2023-11-01
AU2021200290B2 (en) 2023-09-14
IL307576A (en) 2023-12-01
AU2023274172B2 (en) 2025-08-07
CA3036250A1 (en) 2018-03-22
EP3512840B1 (en) 2024-03-06
AU2021200290A1 (en) 2021-03-18
IL265108A (es) 2019-04-30
EP4289425A2 (en) 2023-12-13
US20220306605A1 (en) 2022-09-29
CA3207747A1 (en) 2018-03-22
US20200361894A1 (en) 2020-11-19
JP2024150786A (ja) 2024-10-23
TWI659022B (zh) 2019-05-11
IL307576B2 (en) 2025-06-01
EP3512840A1 (en) 2019-07-24
EP4289425A3 (en) 2024-08-07
KR20240042153A (ko) 2024-04-01
IL265108B2 (en) 2024-03-01
KR20220084439A (ko) 2022-06-21
US12312326B2 (en) 2025-05-27
US11370775B2 (en) 2022-06-28
CA3036250C (en) 2023-09-26
US20220267301A1 (en) 2022-08-25
AU2023274172A1 (en) 2023-12-21
JP2022065012A (ja) 2022-04-26
NZ779170A (en) 2025-08-29
JP2019526604A (ja) 2019-09-19
AU2017326359B2 (en) 2021-02-04
MX2019002726A (es) 2019-09-23
WO2018053161A1 (en) 2018-03-22
CN110234635A (zh) 2019-09-13
JP7551051B2 (ja) 2024-09-17
NZ751050A (en) 2021-08-27

Similar Documents

Publication Publication Date Title
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CU24389B1 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
BR112018011709A2 (pt) inibidores bicíclicos de pad4
EA201790992A1 (ru) Иммунорегуляторные агенты
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
PE20210470A1 (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
MX388562B (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
EA201591509A1 (ru) Ингибиторы cdc7
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).